nature portfolio

Corresponding author(s):	P. Lynne Howell
Last updated by author(s):	Oct 13, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

C-	ŀ٦	+1	ict	ics
S	ιa	ι	IJι	105

For	all statistical ar	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a	Confirmed					
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
	The statis Only comn	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
\boxtimes	A description of all covariates tested					
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give P values as exact values whenever suitable.					
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
\boxtimes	\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated					
		Our web collection on statistics for biologists contains articles on many of the points above.				
So	ftware an	d code				
Poli	cy information	about <u>availability of computer code</u>				
Da	ata collection	Microsoft Excel version 16.54.				
Da	ata analysis	Graphpad Prism version 9 and Statistica Software version 14.				
For m	nanuscripts utilizin	g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and				

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data generated or analysed during this current study are included in this published article and its supporting information

Human rese	arch parti	icipants			
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.			
Reporting on sex and gender N/A		N/A			
Population characteristics		N/A			
Recruitment N/		N/A			
Ethics oversight		N/A			
Note that full informa	ation on the appi	roval of the study protocol must also be provided in the manuscript.			
Field-spe	ecific re	eporting			
Please select the or	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
X Life sciences	E	Behavioural & social sciences			
For a reference copy of t	the document with	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
Life scier	nces sti	udy design			
All studies must dis	close on these	points even when the disclosure is negative.			
Sample size	sufficient as we	mple size was determined using both technical and biological replicates, stated in the methods for each experiment. These sample sizes are fficient as we ensured to have 3 or more total replicates to increase statistical power, and referred to the relevant literature to guide our mple size choices.			
Data exclusions	No data was ex	ccluded.			
Replication		To verify reproducibility of the experimental findings, we ensured to have both technical and biological replicates. We confirm all replication attempts were successful.			
Randomization		Strains used in our study were allocated by the strain type i.e. the wild type and each mutant strain were grouped individually. Covariates were not relevant to control for our study as we found no confounding variables in our data.			
Blinding	The investigators responsible for our infection model data using C. elegans and Drosophila were blinded to group allocation during data collection and analysis. Blinding was not performed for other experiments due to the nature of the experimental set up and the experiment being performed by a sole investigator.				
Reporting for specific materials, systems and methods					
·		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & experimental systems Methods					
n/a Involved in th	,	n/a Involved in the study			
Antibodies		ChIP-seq			
Palaeontology and archaeology MRI-based neuroimaging Animals and other organisms					

Antibodies

Antibodies used

Clinical data
Dual use research of concern

Two antibodies were used in this study. A polyclonal Pel antibody that cannot be commercially purchased. The production of this antibody is found in PMID: 26311845 and was provided to us by the lab of the corresponding author. A polyclonal PilF antibody was

used as a loading control, and also cannot be commercially purchased. We previously published the generation of this antibody in PMID: 18776008.

Validation

The validation of the Pel antibody is shown in PMID: 26311845, in our work using the relevant positive and negative controls, and its application is to detect the Pel exopolysaccharide. The validation of the PilF antibody is shown in PMID: 18776008 and its application is to detect the PilF protein which is involved in localization of the Type IV pilus. We used this antibody in our work as a loading control specifically, as Pseudomonas aeruginosa contains PilF.

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals This study did not involve laboratory animals.

Wild animals This study did not involve wild animals.

Reporting on sex

Our findings using Drosophila melanogaster applied to only one sex, male. Sex was considered in the study design, which was previously developed in PMID: 21998591 because we were examining survival and needed to account for the potential of female flies being pregnant and confounding the data. The flies were assigned sex by standard visual inspection under a microscope. No data was

being pregnant and confounding the data. The flies were assigned sex by standard visual inspection under a microscope. No data was disaggregated for sex because we only used male flies. Sex-based analyses were not performed because we only used male flies.

Field-collected samples This study does not contain samples collected from the field.

Ethics oversight No ethical approval or guidance was required because we used nematodes and insects in our study, not animals.

Note that full information on the approval of the study protocol must also be provided in the manuscript.